Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.

Mazumder MK, Paul R, Phukan BC, Dutta A, Chakrabarty J, Bhattacharya P, Borah A.

Med Hypotheses. 2018 Aug;117:54-58. doi: 10.1016/j.mehy.2018.06.009. Epub 2018 Jun 8.

PMID:
30077198
2.

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

Jaiteh M, Zeifman A, Saarinen M, Svenningsson P, Bréa J, Loza MI, Carlsson J.

J Med Chem. 2018 Jun 28;61(12):5269-5278. doi: 10.1021/acs.jmedchem.8b00204. Epub 2018 Jun 15.

PMID:
29792714
3.

Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach.

Ambure P, Bhat J, Puzyn T, Roy K.

J Biomol Struct Dyn. 2018 Apr 23:1-25. doi: 10.1080/07391102.2018.1456975. [Epub ahead of print]

PMID:
29578387
4.

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Rauhamäki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pasanen M, Manivannan E, Ahinko M, Koskimies P, Nyberg N, Huuskonen P, Multamäki E, Pasanen M, Juvonen RO, Raunio H, Huuskonen J, Pentikäinen OT.

Front Chem. 2018 Mar 2;6:41. doi: 10.3389/fchem.2018.00041. eCollection 2018.

5.

Synthesis and Biological Evaluation of New Thiosemicarbazone Derivative Schiff Bases as Monoamine Oxidase Inhibitory Agents.

Çavuşoğlu BK, Sağlık BN, Osmaniye D, Levent S, Acar Çevik U, Karaduman AB, Özkay Y, Kaplancıklı ZA.

Molecules. 2017 Dec 28;23(1). pii: E60. doi: 10.3390/molecules23010060.

6.

A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.

Chan HH, Tse MK, Kumar S, Zhuo L.

Eur J Pharmacol. 2018 Jan 5;818:254-262. doi: 10.1016/j.ejphar.2017.10.023. Epub 2017 Oct 17.

PMID:
29050969
7.

Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.

Sang Z, Wang K, Wang H, Yu L, Wang H, Ma Q, Ye M, Han X, Liu W.

Bioorg Med Chem Lett. 2017 Nov 15;27(22):5053-5059. doi: 10.1016/j.bmcl.2017.09.055. Epub 2017 Sep 28.

PMID:
29033232
8.

Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.

Yang HL, Cai P, Liu QH, Yang XL, Fang SQ, Tang YW, Wang C, Wang XB, Kong LY.

Bioorg Med Chem. 2017 Nov 1;25(21):5917-5928. doi: 10.1016/j.bmc.2017.08.048. Epub 2017 Sep 27.

PMID:
28988627
9.

Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.

Liu X, Shi Y, Deng Y, Dai R.

Pharmacogn Mag. 2017 Jul-Sep;13(51):358-362. doi: 10.4103/pm.pm_384_16. Epub 2017 Jul 19.

10.

Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties.

Cai P, Fang SQ, Yang XL, Wu JJ, Liu QH, Hong H, Wang XB, Kong LY.

ACS Chem Neurosci. 2017 Nov 15;8(11):2496-2511. doi: 10.1021/acschemneuro.7b00257. Epub 2017 Aug 25.

PMID:
28806057
11.

Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.

Costas-Lago MC, Besada P, Rodríguez-Enríquez F, Viña D, Vilar S, Uriarte E, Borges F, Terán C.

Eur J Med Chem. 2017 Oct 20;139:1-11. doi: 10.1016/j.ejmech.2017.07.045. Epub 2017 Jul 25.

PMID:
28797881
12.

Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?

Fonseca A, Reis J, Silva T, Matos MJ, Bagetta D, Ortuso F, Alcaro S, Uriarte E, Borges F.

J Med Chem. 2017 Aug 24;60(16):7206-7212. doi: 10.1021/acs.jmedchem.7b00918. Epub 2017 Aug 10.

PMID:
28753307
13.

The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro.

Bartl J, Palazzesi F, Parrinello M, Hommers L, Riederer P, Walitza S, Grünblatt E.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):281-288. doi: 10.1016/j.pnpbp.2017.07.002. Epub 2017 Jul 8.

PMID:
28690202
14.
15.

Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.

Lee J, Lee Y, Park SJ, Lee J, Kim YS, Suh YG, Lee J.

Eur J Med Chem. 2017 Apr 21;130:365-378. doi: 10.1016/j.ejmech.2017.02.059. Epub 2017 Mar 1.

PMID:
28273563
16.

Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors.

Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.

Eur J Med Chem. 2017 Feb 15;127:470-492. doi: 10.1016/j.ejmech.2017.01.011. Epub 2017 Jan 11.

PMID:
28107736
17.

Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.

Cruz-Monteagudo M, Borges F, Cordeiro MNDS, Helguera AM, Tejera E, Paz-Y-Mino C, Sanchez-Rodriguez A, Perera-Sardina Y, Perez-Castillo Y.

Curr Neuropharmacol. 2017 Nov 14;15(8):1117-1135. doi: 10.2174/1570159X15666170116145316.

18.

The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.

Zarmouh NO, Eyunni SK, Soliman KF.

BMC Complement Altern Med. 2017 Jan 10;17(1):34. doi: 10.1186/s12906-016-1525-y.

19.

Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.

Perez-Castillo Y, Helguera AM, Cordeiro MNDS, Tejera E, Paz-Y-Mino C, Sanchez-Rodriguez A, Borges F, Cruz-Monteagudo M.

Curr Neuropharmacol. 2017 Nov 14;15(8):1107-1116. doi: 10.2174/1570159X15666170109143757.

20.

Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.

Xiao G, Li Y, Qiang X, Xu R, Zheng Y, Cao Z, Luo L, Yang X, Sang Z, Su F, Deng Y.

Bioorg Med Chem. 2017 Feb 1;25(3):1030-1041. doi: 10.1016/j.bmc.2016.12.013. Epub 2016 Dec 9.

PMID:
28011206

Supplemental Content

Loading ...
Support Center